Back to Newsroom

CHINA FOOD AND DRUG ADMINISTRATION ACCEPTS IND FOR PIVOTAL STUDY OF AMITIZA(R) (LUBIPROSTONE)

BETHESDA, Md., June 15, 2015 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global pharmaceutical company, today announced that the China Food and Drug Administration (CFDA) has accepted an Investigational New Drug (IND) application for a pivotal study of AMITIZA in patients with chronic idiopathic constipation. Harbin Gloria Pharmaceuticals Co., Ltd. (Gloria) will design and conduct the study under the terms of its exclusive license, development, commercialization and supply agreement with Sucampo for AMITIZA in China. In connection with the IND acceptance, Sucampo will receive $500,000 from Gloria, which is the second tranche of the $1.5 millionupfront payment agreed to as part of the licensing agreement.

Click here to read more